US2018216062A1PendingUtilityA1
Method for Enzymatic Treatment of Tissue Products
Est. expiryApr 28, 2031(~4.8 yrs left)· nominal 20-yr term from priority
A61L 27/3687A61L 2430/40C12N 5/0068A61L 27/56A61L 27/3604
62
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Methods for treating tissue matrices and tissue matrices produced according to the methods are provided. The methods can include treating a tissue matrix with a proteolytic enzyme to produce a desired pliability of the tissue matrix and/or to control the immunogenicity of the tissue matrix. The methods can also comprise performing an assay to determine if contacting the at least one collagen-containing tissue matrix with a proteolytic enzyme has altered the at least one collagen-containing tissue matrix to reduce a human immune response to the tissue matrix.
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1 . A tissue matrix prepared by a process comprising:
selecting at least one collagen-containing tissue matrix; contacting the at least one collagen-containing tissue matrix with a first solution comprising a proteolytic enzyme to create an enzyme-treated tissue matrix; and treating the enzyme-treated tissue matrix with a second solution to remove at least some of the cells and cellular components from the enzyme-treated tissue matrix, wherein the enzyme comprises alcalase and is contacted with the at least one collagen-containing tissue matrix under conditions sufficient to produce a desired level of pliability in the at least one collagen-containing tissue matrix.
2 . The tissue matrix of claim 1 , wherein the tissue matrix treatment with the second solution is performed under conditions that produce an acellular tissue matrix.
3 . The tissue matrix of claim 1 , wherein the at least one collagen-containing tissue matrix comprises a dermal tissue matrix.
4 . The tissue matrix of claim 3 , wherein the dermal tissue matrix does not contain an epidermis.
5 . The tissue matrix of claim 1 , wherein the at least one collagen-containing tissue matrix is obtained from a tissue selected from fascia, pericardial tissue, dura, umbilical cord tissue, placental tissue, cardiac valve tissue, ligament tissue, tendon tissue, arterial tissue, venous tissue, neural connective tissue, urinary bladder tissue, ureter tissue, and intestinal tissue.
6 . The tissue matrix of claim 1 , wherein the at least one collagen-containing tissue matrix is contacted with the first solution comprising the proteolytic enzyme under conditions that do not produce an undesirable change in at least one of tensile strength, tear strength, suture strength, creep resistance, burst strength, thermal transition temperature, collagenase susceptibility or combinations thereof.
7 . The tissue matrix of claim 1 , wherein the at least one collagen-containing tissue matrix is contacted with the first solution comprising the proteolytic enzyme under conditions that do not cause a statistically significant change in tensile strength, tear strength, suture strength, creep resistance, thermal transition temperature, collagenase susceptibility or combinations thereof.
8 . The tissue matrix of claim 1 , wherein the second solution includes a detergent.
9 . The tissue matrix of claim 1 , wherein all of the cells and cellular components are removed from the enzyme-treated tissue matrix.
10 . A method for treating a tissue matrix, comprising:
selecting at least one collagen-containing tissue matrix; contacting the at least one collagen-containing tissue matrix with a first solution comprising a proteolytic enzyme to create an enzyme-treated tissue matrix; and treating the enzyme-treated tissue matrix with a second solution to remove at least some of the cells and cellular components from the enzyme-treated tissue matrix, wherein the enzyme comprises alcalase and is contacted with the at least one collagen-containing tissue matrix under conditions sufficient to produce a desired level of pliability in the at least one collagen-containing tissue matrix.
11 . The method of claim 10 , wherein the tissue matrix treatment with the second solution is performed under conditions that produce an acellular tissue matrix.
12 . The method of claim 10 , wherein the at least one collagen-containing tissue matrix comprises a dermal tissue matrix.
13 . The method of claim 12 , wherein the dermal tissue matrix does not contain an epidermis.
14 . The method of claim 10 , wherein the at least one collagen-containing tissue matrix is obtained from a tissue selected from fascia, pericardial tissue, dura, umbilical cord tissue, placental tissue, cardiac valve tissue, ligament tissue, tendon tissue, arterial tissue, venous tissue, neural connective tissue, urinary bladder tissue, ureter tissue, and intestinal tissue.
15 . The method of claim 10 , wherein the at least one collagen-containing tissue matrix is contacted with the first solution comprising the proteolytic enzyme under conditions that do not produce an undesirable change in at least one of tensile strength, tear strength, suture strength, creep resistance, burst strength, thermal transition temperature, collagenase susceptibility or combinations thereof.
16 . The method of claim 10 , wherein the at least one collagen-containing tissue matrix is contacted with the first solution comprising the proteolytic enzyme under conditions that do not cause a statistically significant change in tensile strength, tear strength, suture strength, creep resistance, thermal transition temperature, collagenase susceptibility or combinations thereof.
17 . The method of claim 10 , wherein the second solution includes a detergent.
18 . The method of claim 10 , including removal of all the cells and cellular components from the enzyme-treated tissue matrix.
19 . The method of claim 10 , wherein the at least one collagen-containing tissue matrix includes two or more tissue matrices.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.